Proactive Investors USA & Canada |
BUZZ-Vectura: all-time high on completing asthma therapy trial
Reuters … ** Vectura up over 5 pct to all-time high & top FTSE 250 mid-cap gainer after it completes a clinical trial for generic asthma therapy VR315 in the U.S., bringing it closer to a commercial launch. ** Drug developer also reveals that its partner for … Drug developer Vectura on a high as asthma treatment completes US clinical trial Vectura Group Completes Clinical Trial For VR315 Asthma Treatment Vectura Completes Clinical Trial For VR315 In US; Stock Up |
View full post on asthma – Google News